Dataset from A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接:
https://doi.org/10.25934/00002517
下载链接
链接失效反馈官方服务:
资源简介:
The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.
创建时间:
2025-06-24



